GSK plc GSK reported third-quarter 2024 core earnings of $1.27 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.16. Core earnings declined 1% year over year on a ...

and the generic version of the drug still costs $300. The price of asthma inhalers has seen a similar increase. These prices are out of reach for many patients. A study in the Journal of the ...

Any Australian who has filled a prescription at the chemist will have been asked if they want a branded product or the generic version. And with consumers looking to cut costs wherever they can ...

A Europol report on criminal networks released in April said the majority of Europe's most dangerous gangs now focused on drug smuggling, mainly dealing in cocaine, cannabis, heroin and synthetic ...

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. In a court decision filed this ...

Drugs such as Novo Nordisk’s blockbuster Ozempic can cut drug and alcohol abuse by up to 50% according to a new study, adding to mounting evidence that the drugs yield health benefits beyond ...

The U.S. Centers for Medicare & Medicaid Services (CMS) has released a preliminary list of 101 generic drugs that would ... lithium and albuterol asthma inhalers, as well as drugs for high ...

Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.

Trelegy Ellipta does not come as a generic drug. Trelegy Ellipta comes in a dry powder inhaler. Each active ingredient in Trelegy Ellipta belongs to a different group of drugs. These include ...

Drug companies are taking advantage of a global climate treaty to boost profits. The treaty, signed by some 120 countries nearly a decade ago, is now providing inhaler makers with a golden escape ...